Vita Verum Medical Bt. — Clinical Trial Site

27 Registered trials

9 Currently recruiting

Organisation

Vita Verum Medical Bt.

Location

Szekesfehervar, Hungary

Identifier

ORG-100039249

Address

Fiskalis Ut 43, 8000, Hungary

Departments

-
#3102
#40499
2504
3102
Metabolic Diseases
N/A
NA
SMed Magankorhaz
Vita Verum Medical
Vita Verum Medical bt.
Vita Verum Medical Egészségügyi Szolgáltató Betéti Társaság
Vita Verum Medical Egeszsegugyi Szolgaltato Bt. (#1)
Vitaverum Medical Bt

Clinical trials at this site (27)

Search interface

A study to test whether different doses of BI 3000202 help people with systemic lupus erythematosus (SLE) Pending

2025-523488-39-00 Systemic lupus erythematosus 4
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with… Recruiting

2024-513965-38-01 Sjögren's Disease 5 2025-06-16
A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting

2022-501354-10-01 axial spondyloarthritis 5 2023-06-21
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus E… Recruiting

2025-523552-31-00 Systemic Lupus Erythematosus 5 2026-05-07
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
Brivekimig for the treatment of moderate to severe hidradenitis suppurativa Recruiting

2025-522333-61-00 Hidradenitis suppurativa 4 2026-01-23
A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig… Recruiting

2025-520519-14-00 Atherosclerotic Cardiovascular Disease 5 2025-09-03
Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS-… Recruiting

2023-505929-14-00 Systemic Lupus Erythematosus 5 2024-05-21
Frexalimab in preservation of endogenous insulin secretion compared to placebo in adults, adolescents and children on top of Insulin therapy… Recruiting

2022-500531-36-00 Type 1 diabetes mellitus 4 2024-02-02
Efficacy and safety of subcutaneous dupilumab for the treatment of adult participants with chronic pruritus of unknown origin (CPUO) Recruiting

2023-508879-36-00 Pruritus 5 2022-04-28
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended

2024-516609-22-00 Primary Sjögren’s Disease 5 2025-04-15
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
Efficacy and safety of subcutaneous dupilumab in participants with asthma/asthmatic wheeze aged 2 to <6 years Ended

2023-504331-41-00 Respiratory tract diseases - Wheezing, Asthma 5 2024-08-02
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic … Ended

2023-503655-10-00 Systemic Lupus Erythematosus (SLE). 5 2023-11-20
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’… Ended

2022-502966-26-01 Sjögren’s syndrome 5 2023-10-27
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
Phase 3 study to evaluate two regimens of ianalumab on top of standardof- care therapy in patients with systemic lupus erythematosus (SIRIUS… Ended

2023-508498-97-00 Systemic Lupus Erythematosus 5 2023-02-03
Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Boo… Ended

2023-510145-25-00 Meningococcal infection 5 2022-08-23
Three-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended

2024-511068-10-00 Sjögren’s Syndrome 5 2022-08-04
Efficacy and safety of Frexalimab (SAR441344) in the treatment of Systemic Lupus Erythematosus Ended

2023-508654-26-00 Systemic lupus erythematosus 4 2022-03-15
A Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background N… Ended

2023-505696-74-00 systemic lupus erythematosus 5 2022-02-10
A study to learn if dapirolizumab pegol is safe and works long-term in people with systemic lupus erythematosus Ended

2023-506368-14-00 Systemic lupus erythematosus (SLE) 5 2021-09-07